Aska Report

Overview

The report describes the company's focus on internal medicine, obstetrics and gynecology, and urology, alongside a portfolio of new drugs and generics. It says ASKA PLAN 2020 progressed generally smoothly and that the company achieved record-high sales for a second consecutive year. The plan's consolidated targets include net sales of ¥70 billion, a 10% operating profit margin and 8% ROE, while consolidated employees totaled 856 as of March 31, 2018.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2017
Period: 1 April 2017 – 31 March 2018
Language: English
Pages
File size
Restatement: Disclosed

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services